Tag: Vertex pharmaceuticals

In January 2025, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine), marking the first new class of oral, non-opioid pain medication to reach the market in over two decades. The development of this new opioid free painkiller offers a potent, non-addictive alternative for managing moderate to severe acute pain in adults.

In January 2025, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine), the first new oral, non-opioid painkiller in over two decades, representing a significant milestone in pain management. This development offers a promising alternative to address the ongoing opioid crisis by providing a powerful, yet non-addictive, option for managing moderate to severe acute pain.